Literature DB >> 3475137

No adverse prognostic influence of hepatitis B virus infection in acute childhood lymphoblastic leukemia.

F Lampert, W R Willems, U Bertram, F Berthold.   

Abstract

In the years 1980-1985 72 children with acute lymphoblastic leukemia were diagnosed and treated by intensive combination chemotherapy (BFM protocols 79, 81, 83). Of these children 33 acquired a Hepatitis B-virus-carrier state with 1983 as the peak year of incidence. Both groups of patients, the infected and the uninfected ones, were comparable as to prognostic factors. All except 8 patients are off chemotherapy after a total duration of treatment of 1 1/2 or 2 years. Probability for event-free survival (life table analysis, maximum observation time 82 months, minimum 12 months) is equal (0.77 vs. 0.75) in both groups. With 3 exceptions, all HBV-infected patients still carry the HBs-antigen in the serum; 22 of the 30 living patients in the infected group developed anti-HBc.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3475137     DOI: 10.1007/BF00631782

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  12 in total

1.  The unexpected outcomes of medical research: serendipity and the Australia antigen. Blumberg BS, Alter HJ, Visnich S. A new antigen in leukemia sera [J Am Med Assoc 1965;191:541-546].

Authors:  Harvey J Alter
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

2.  [Hepatitis B endemic in leukemic children].

Authors:  W R Willems; H Bauer; F Lampert; U Westphal
Journal:  Dtsch Med Wochenschr       Date:  1984-12-14       Impact factor: 0.628

3.  Posttransfusion hepatitis in acute myelogenous leukemia. Effect on survival.

Authors:  K A Foon; C Yale; K Clodfelter; R P Gale
Journal:  JAMA       Date:  1980-10-17       Impact factor: 56.272

4.  [Estimation of tumor cell mass in childhood acute lymphoblastic leukemia: prognostic significance and practical application].

Authors:  H J Langermann; G Henze; M Wulf; H Riehm
Journal:  Klin Padiatr       Date:  1982 Jul-Aug       Impact factor: 1.349

5.  Acute and chronic hepatitis in childhood leukemia: a multicentric study from the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (AIL-AIEOP).

Authors:  A Locasciulli; A Alberti; F Rossetti; M Santamaria; N Santoro; E Madon; R Miniero; M Lo Curto; P Tamaro; P Paolucci
Journal:  Med Pediatr Oncol       Date:  1985

6.  Hepatitis B virus markers in children with acute leukemia: the effect of chemotherapy.

Authors:  A Locasciulli; M Santamaria; G Masera; E Schiavon; A Alberti; G Realdi
Journal:  J Med Virol       Date:  1985-01       Impact factor: 2.327

7.  Adverse prognostic influence of hepatitis B virus infection in acute lymphoblastic leukemia.

Authors:  L Ratner; N Peylan-Ramu; R Wesley; D G Poplack
Journal:  Cancer       Date:  1986-09-01       Impact factor: 6.860

8.  Posttransfusion hepatitis in acute nonlymphocytic leukemia: lack of a beneficial influence.

Authors:  M Markman; H G Braine; W P Vaughan
Journal:  Med Pediatr Oncol       Date:  1983

9.  [Hepatitis B infections in cytostatically treated children].

Authors:  G Janssen; D Schwamborn; F Hornschuh; H Jürgens; U Göbel
Journal:  Klin Padiatr       Date:  1986 May-Jun       Impact factor: 1.349

10.  [BFM study 1981/83 of the treatment of highly malignant non-Hodgkin's lymphoma in children: results of therapy stratified according to histologic immunological type and clinical stage].

Authors:  S Müller-Weihrich; J Beck; G Henze; A Jobke; B Kornhuber; F Lampert; R Ludwig; G Prindull; G Schellong; H J Spaar
Journal:  Klin Padiatr       Date:  1984 May-Jun       Impact factor: 1.349

View more
  1 in total

1.  Genotyping by multiplex polymerase chain reaction for detection of endemic hepatitis B virus transmission.

Authors:  R Repp; S Rhiel; K H Heermann; S Schaefer; C Keller; P Ndumbe; F Lampert; W H Gerlich
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.